Exit Case: AstraZeneca PLC

AstraZeneca PLC (LSE: AZN) is an FTSE 100 listed science-led biopharmaceutical company, which focuses on the development, commercialization, and discovery of prescription medicines. This Report covers the Key Recommendation Rationale, and Conclusion on the stock.

AstraZeneca PLC has been a part of the ‘Value Model Portfolio’ since 16 May 2025, however, considering the recent rally, trading above resistance levels in the stock, support & resistance levels, and ~17.44% upside from the entry price, an ‘Exit’ is recommended on the stock near the resistance of GBX 12,160.00, (as of current market price on 05^th September 2025 at 01:13 PM GMT+1). 

AstraZeneca PLC (LSE: AZN) is a part of Kalkine’s Value Model Portfolio, which has approached its resistance level around which an exit case emerges.

1.1 Support and Resistance Summary as provided in our last published report dated 16 May 2025.

1.2 AstraZeneca PLC

1.3 New Entry Case: Schroders PLC (LSE: SDR)

Schroders PLC (LSE: SDR) is an FTSE 100 index listed UK-based investment management firm providing active asset management, advisory, and wealth management services to individuals, family offices, and charities. The company operates through two main divisions: Asset Management and Wealth Management. The Asset Management segment focuses on investment management, including advisory services for equities, fixed income, multi-asset portfolios, private assets, and alternative investments.

An ‘Entry’ is recommended in the ‘Value Model Portfolio’ at the current market price of GBX 369.60, as on (05th September 2025 at 12:59 PM GMT+1).

Schroders PLC (LSE: SDR) has been identified as the new entry to our Value Model Portfolio.

2.1 Support and Resistance Summary (as on 05th September 2025)

2.2 Technical Price Chart (LSE: SDR)

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency as of 05 September 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings.

Disclaimer

This information should not be relied upon as personal financial advice by Kalkine on (i) the stocks or (ii) the use or suitability of the model portfolios. Only an investor knows about their circumstances to make an investment decision.

Model Portfolio has been prepared for illustrative purpose only and does not take into account the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the information, consider its appropriateness, having regard to their objectives, financial situation and needs. Past performance is not necessarily indicative of future performance results. Actual investment returns will vary, and the Growth of investments can go up or down.